

**Remarks**

The pending claims were subject to a Restriction Requirement and were assigned the following Groups:

- Group I. Claims 1-6 and 23 (in part) drawn to substantially purified salivary *Lu. longipalpis* polypeptide and a composition comprising said polypeptide;
- Group II. Claims 7-18 and 24 (in part) drawn to an isolated polynucleotide, recombinant expression vector, and host cell, an immunogenic composition DNA;
- Group III. Claims 19-22 (in part) drawn to an antibody;
- Group IV. Claims 25-30 (in part) drawn to a method for inducing an immune response;
- Group V. Claim 31 (in part) drawn to a method for inhibiting a symptom of a *Leishmania* infection;
- Group VI. Claims 32 and 33 (in part) drawn to a method of manufacturing polypeptide as a medicament;
- Group VII. Claims 32 and 33 (in part) drawn a method of manufacturing nucleic acid as a medicament; and
- Group VIII. Claims 34-38 (in part) drawn to a method of diagnosing *Leishmania* infection using polypeptide.

However, Applicants note that a number of the claims cited as being a part of these Groups (claims 3, 9, 22, 27, 32, and 33) were canceled by preliminary amendment on April 29, 2005. Thus, as only claims 1, 2, 4-8, 10-21, 23-26, 28-31, and 34-38 are pending in this application, Groups VI and VII, directed to canceled claims 32 and 33, do not exist. Applicants respectfully request that the preliminary amendment submitted on April 29, 2005, and which accompanied the filing of this National stage application, be acknowledged in a subsequent communication from the United States Patent and Trademark Office.

Applicants elect Examiner's Group I (claims 1-6 and 23, in part), drawn to a substantially purified salivary *Lu. longipalpis* polypeptide and a composition comprising said polypeptide. As requested in the Office action, applicants further elect SEQ ID NO: 15 (referred to as LJL143 in the specification) for prosecution.

**Conclusion**

It is believed that the application is in condition for substantive examination. If any minor matters remain to be addressed prior to examination, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Anne Carlson/  
Anne Carlson, Ph.D.  
Registration No. 47,472